Page last updated: 2024-10-21

alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Acute Confusional Senile Dementia

alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid has been researched along with Acute Confusional Senile Dementia in 29 studies

alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.

Research Excerpts

ExcerptRelevanceReference
"Furthermore, in Alzheimer's disease we hypothesized that cells at risk for developing AD neuropathology will express certain combinations of glutamate receptor subunits that form channels with increased permeability to Ca2+."2.47Age- and disease-related neuroplasticity of chemically identified neuronal circuits: a tribute to Professor Erminio Costa. ( Armstrong, D, 2011)
"Key pathological features of Alzheimer's disease (AD) include build-up of amyloid β (Aβ), which promotes synaptic abnormalities and ultimately leads to neuronal cell death."1.91Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration. ( Ainge, JA; Doherty, G; Duncan, S; Flewitt, I; Hamilton, K; Harvey, J; Holiday, A; MacLeod, B; Malekizadeh, Y; Manolescu, C, 2023)
"As a neurodegenerative disease, Alzheimer's disease (AD) seriously affects the health of older people."1.72A Class I HDAC Inhibitor Rescues Synaptic Damage and Neuron Loss in APP-Transfected Cells and APP/PS1 Mice through the GRIP1/AMPA Pathway. ( Chen, J; Chen, L; Chu, H; Guo, Y; Han, Y; Liu, J; Ma, H; Wang, C; Yu, X; Zhang, C, 2022)
"In 2-month-old mice, no β-amyloid plaques deposition, but the presence of soluble oligomers, were found in CA1 area but not in dentate gyrus (DG)."1.42Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease. ( Borsello, T; Calabresi, P; Costa, C; de Iure, A; Di Filippo, M; Ghiglieri, V; Sclip, A; Tantucci, M; Tozzi, A, 2015)
"Cognitive decline in Alzheimer's disease (AD) stems from the progressive dysfunction of synaptic connections within cortical neuronal microcircuits."1.33Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. ( Burnashev, N; Farkas, T; Fülöp, L; Harkany, T; Härtig, W; Holmgren, C; Min, R; Penke, B; Shemer, I; Sousa, KM; Tanila, H; Zilberter, M; Zilberter, Y, 2006)
"Since Alzheimer's disease is known to be associated with down-regulation of the cholinergic and N-methyl-D-aspartate (NMDA) systems, most of these drugs inhibit acetylcholinesterase, potentiate the activity of nicotinic acetylcholine receptors (nAChRs), or modulate NMDA receptors."1.33In vitro galantamine-memantine co-application: mechanism of beneficial action. ( Huang, J; Marszalec, W; Narahashi, T; Toth, PT; Yeh, JZ; Zhao, X, 2006)

Research

Studies (29)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's9 (31.03)18.2507
2000's5 (17.24)29.6817
2010's8 (27.59)24.3611
2020's7 (24.14)2.80

Authors

AuthorsStudies
Guo, C1
Wen, D1
Zhang, Y1
Mustaklem, R1
Mustaklem, B1
Zhou, M1
Ma, T1
Ma, YY1
Han, Y1
Chen, L1
Liu, J1
Chen, J1
Wang, C1
Guo, Y1
Yu, X1
Zhang, C1
Chu, H1
Ma, H1
Doherty, G3
Holiday, A3
Malekizadeh, Y3
Manolescu, C3
Duncan, S3
Flewitt, I3
Hamilton, K3
MacLeod, B3
Ainge, JA3
Harvey, J3
Lilek, J1
Ajroud, K1
Feldman, AZ1
Krishnamachari, S1
Ghourchian, S1
Gefen, T1
Spencer, CL1
Kawles, A1
Mao, Q1
Tranovich, JF1
Jack, CR1
Mesulam, MM1
Reichard, RR1
Zhang, H1
Murray, ME1
Knopman, D1
Dickson, DW1
Petersen, RC1
Smith, B1
Ashe, KH1
Mielke, MM1
Nelson, KM1
Flanagan, ME1
Abghari, M1
Vu, JTCM1
Eckberg, N1
Aldana, BI1
Kohlmeier, KA1
Fernández-Pérez, EJ1
Gallegos, S1
Armijo-Weingart, L1
Araya, A1
Riffo-Lepe, NO1
Cayuman, F1
Aguayo, LG1
Fani, G1
Mannini, B1
Vecchi, G1
Cascella, R1
Cecchi, C1
Dobson, CM1
Vendruscolo, M1
Chiti, F1
Bretin, S1
Krazem, A1
Henkous, N1
Froger-Colleaux, C1
Mocaer, E1
Louis, C1
Perdaems, N1
Marighetto, A1
Beracochea, D1
Hettinger, JC1
Lee, H1
Bu, G1
Holtzman, DM1
Cirrito, JR1
Baglietto-Vargas, D1
Prieto, GA1
Limon, A1
Forner, S1
Rodriguez-Ortiz, CJ1
Ikemura, K1
Ager, RR1
Medeiros, R1
Trujillo-Estrada, L1
Martini, AC1
Kitazawa, M1
Davila, JC1
Cotman, CW1
Gutierrez, A1
LaFerla, FM1
Gong, B1
Pan, Y1
Zhao, W1
Knable, L1
Vempati, P1
Begum, S1
Ho, L1
Wang, J1
Yemul, S1
Barnum, S1
Bilski, A1
Gong, BY1
Pasinetti, GM1
Wang, Y1
Mattson, MP1
Tozzi, A1
Sclip, A1
Tantucci, M1
de Iure, A1
Ghiglieri, V1
Costa, C1
Di Filippo, M1
Borsello, T1
Calabresi, P1
Armstrong, D1
Vellas, B1
Pesce, A1
Robert, PH1
Aisen, PS1
Ancoli-Israel, S1
Andrieu, S1
Cedarbaum, J1
Dubois, B1
Siemers, E1
Spire, JP1
Weiner, MW1
May, TS1
Louzada, PR1
Paula Lima, AC1
Mendonca-Silva, DL1
Noël, F1
De Mello, FG1
Ferreira, ST1
Shemer, I1
Holmgren, C1
Min, R1
Fülöp, L1
Zilberter, M1
Sousa, KM1
Farkas, T1
Härtig, W1
Penke, B1
Burnashev, N1
Tanila, H1
Zilberter, Y1
Harkany, T1
Zhao, X1
Marszalec, W1
Toth, PT1
Huang, J1
Yeh, JZ1
Narahashi, T1
Bowen, DM1
Procter, AW1
Mann, DM1
Snowden, JS1
Esiri, MM1
Neary, D1
Francis, PT1
Muir, JL1
Page, KJ1
Sirinathsinghji, DJ1
Robbins, TW1
Everitt, BJ1
Weiss, JH1
Yin, HZ1
Choi, DW1
Yasuda, RP1
Ikonomovic, MD1
Sheffield, R1
Rubin, RT1
Wolfe, BB1
Armstrong, DM1
Krogsgaard-Larsen, P1
Wahl, P1
Schousboe, A1
Madsen, U1
Hansen, JJ1
Vickers, JC1
Huntley, GW1
Edwards, AM1
Moran, T1
Rogers, SW1
Heinemann, SF1
Morrison, JH1
Ulus, IH1
Wurtman, RJ1
Zhang, JM1
Hu, GY1
Dewar, D3
Chalmers, DT3
Graham, DI3
McCulloch, J3
Shand, A1
Brooks, DN1

Reviews

3 reviews available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Acute Confusional Senile Dementia

ArticleYear
Age- and disease-related neuroplasticity of chemically identified neuronal circuits: a tribute to Professor Erminio Costa.
    Pharmacological research, 2011, Volume: 64, Issue:4

    Topics: Age Factors; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; A

2011
Excitotoxic lesions of basal forebrain cholinergic neurons: effects on learning, memory and attention.
    Behavioural brain research, 1993, Nov-30, Volume: 57, Issue:2

    Topics: Acetylcholine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals;

1993
Excitatory amino acid research in Alzheimer's disease: enhancement and blockade of receptor functions.
    Biochemical Society transactions, 1993, Volume: 21, Issue:1

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Humans; Iboten

1993

Other Studies

26 other studies available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Acute Confusional Senile Dementia

ArticleYear
Amyloid-β oligomers in the nucleus accumbens decrease motivation via insertion of calcium-permeable AMPA receptors.
    Molecular psychiatry, 2022, Volume: 27, Issue:4

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides;

2022
A Class I HDAC Inhibitor Rescues Synaptic Damage and Neuron Loss in APP-Transfected Cells and APP/PS1 Mice through the GRIP1/AMPA Pathway.
    Molecules (Basel, Switzerland), 2022, Jun-29, Volume: 27, Issue:13

    Topics: Adaptor Proteins, Signal Transducing; Aged; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid

2022
Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration.
    Journal of neurochemistry, 2023, Volume: 165, Issue:6

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides;

2023
Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration.
    Journal of neurochemistry, 2023, Volume: 165, Issue:6

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides;

2023
Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration.
    Journal of neurochemistry, 2023, Volume: 165, Issue:6

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides;

2023
Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration.
    Journal of neurochemistry, 2023, Volume: 165, Issue:6

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides;

2023
Accumulation of pTau231 at the Postsynaptic Density in Early Alzheimer's Disease.
    Journal of Alzheimer's disease : JAD, 2023, Volume: 92, Issue:1

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Brain; Cognitive Dysfun

2023
Decanoic Acid Rescues Differences in AMPA-Mediated Calcium Rises in Hippocampal CA1 Astrocytes and Neurons in the 5xFAD Mouse Model of Alzheimer's Disease.
    Biomolecules, 2023, 09-27, Volume: 13, Issue:10

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides;

2023
Changes in neuronal excitability and synaptic transmission in nucleus accumbens in a transgenic Alzheimer's disease mouse model.
    Scientific reports, 2020, 11-11, Volume: 10, Issue:1

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Biomarkers; Di

2020
Aβ Oligomers Dysregulate Calcium Homeostasis by Mechanosensitive Activation of AMPA and NMDA Receptors.
    ACS chemical neuroscience, 2021, 02-17, Volume: 12, Issue:4

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides;

2021
Synergistic enhancing-memory effect of donepezil and S 47445, an AMPA positive allosteric modulator, in middle-aged and aged mice.
    Psychopharmacology, 2018, Volume: 235, Issue:3

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Benzoxazines;

2018
AMPA-ergic regulation of amyloid-β levels in an Alzheimer's disease mouse model.
    Molecular neurodegeneration, 2018, 05-15, Volume: 13, Issue:1

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides;

2018
Impaired AMPA signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer's disease.
    Aging cell, 2018, Volume: 17, Issue:4

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Cytoskeleton;

2018
IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway.
    Molecular immunology, 2013, Volume: 56, Issue:4

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Protein Pr

2013
L-type Ca2+ currents at CA1 synapses, but not CA3 or dentate granule neuron synapses, are increased in 3xTgAD mice in an age-dependent manner.
    Neurobiology of aging, 2014, Volume: 35, Issue:1

    Topics: Aging; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Pep

2014
Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease.
    Neurobiology of aging, 2015, Volume: 36, Issue:1

    Topics: Aging; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Pro

2015
AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials.
    Alzheimer's & dementia : the journal of the Alzheimer's Association, 2011, Volume: 7, Issue:4

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Cholinesterase Inhibito

2011
Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, Volume: 18, Issue:3

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Protein Pr

2004
Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors.
    The European journal of neuroscience, 2006, Volume: 23, Issue:8

    Topics: Action Potentials; Age Factors; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer

2006
In vitro galantamine-memantine co-application: mechanism of beneficial action.
    Neuropharmacology, 2006, Volume: 51, Issue:7-8

    Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolep

2006
Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy.
    Psychopharmacology, 2008, Volume: 196, Issue:4

    Topics: Aged; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Choline O-Acetylt

2008
Basal forebrain cholinergic neurons are selectively vulnerable to AMPA/kainate receptor-mediated neurotoxicity.
    Neuroscience, 1994, Volume: 60, Issue:3

    Topics: Acetylcholine; Acetylcholinesterase; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzhe

1994
Reduction of AMPA-selective glutamate receptor subunits in the entorhinal cortex of patients with Alzheimer's disease pathology: a biochemical study.
    Brain research, 1995, Apr-24, Volume: 678, Issue:1-2

    Topics: Aged; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Blotting, Western

1995
Quantitative localization of AMPA/kainate and kainate glutamate receptor subunit immunoreactivity in neurochemically identified subpopulations of neurons in the prefrontal cortex of the macaque monkey.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 1993, Volume: 13, Issue:7

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Antibodies; Bi

1993
Metabotropic glutamate receptor agonists increase release of soluble amyloid precursor protein derivatives from rat brain cortical and hippocampal slices.
    The Journal of pharmacology and experimental therapeutics, 1997, Volume: 281, Issue:1

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Protein Pr

1997
Huperzine A, a nootropic alkaloid, inhibits N-methyl-D-aspartate-induced current in rat dissociated hippocampal neurons.
    Neuroscience, 2001, Volume: 105, Issue:3

    Topics: Alkaloids; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Cel

2001
Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease: an autoradiographic study of the hippocampus.
    Brain research, 1991, Jul-05, Volume: 553, Issue:1

    Topics: Aged; Aged, 80 and over; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease

1991
Selective reduction of quisqualate (AMPA) receptors in Alzheimer cerebellum.
    Annals of neurology, 1990, Volume: 28, Issue:6

    Topics: Aged; Aged, 80 and over; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease

1990
Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type.
    Proceedings of the National Academy of Sciences of the United States of America, 1990, Volume: 87, Issue:4

    Topics: Aged; Aged, 80 and over; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease

1990